Basic Pharma Group: The Trusted CMO for Pre-Filled Syringes
pharmatechoutlook

Basic Pharma Group: The Trusted CMO for Pre-Filled Syringes

Follow Basic Pharma Group on :

Cyrille Delahaye, Director of operations, Basic Pharma GroupCyrille Delahaye, Director of operations
In the changing healthcare landscape, patients’ preferences are shifting towards more parenteral, self-administration of drugs. As a result, assisted drug delivery techniques from multi-dose or single-dose vials are becoming obsolete. The pharmaceutical industries, consequently, is seeking out newer and cost-effective drug delivery methods that ensure patients’ and healthcare workers’ safety, and at the same time, improve the efficiency of drugs. At the helm of these requirements, pre-filled syringes (PFS) have emerged as one of the fastest-growing choices for unit-dose medication and a more convenient way to self-administer drugs. Healthcare markets are increasingly turning to pre-packaged medicines in pre-filled, single-use syringes, as more and more companies are recognising the benefits of this latest innovation.

However, with the rising demand for PFS, it is also crucial for pharmaceutical companies to ensure there is no contamination during the bulk production of PFS. It is, therefore, imperative for these companies to adhere to the increasing demand for flexible and specific aseptic filling services. The CMO that helps pharma companies achieve such a feat is the Basic Pharma Group.

Basic Pharma maintains an entirely multi-purpose, aseptic PFS and vial filling line for liquid and lyophilized injectable products. Housed at the company’s GMP-certified facility at the Brightlands Chemelot Research Campus in the Netherlands, the aseptic filling line operates in a class ‘A’ isolator, which guarantees an aseptic production process, thus ensuring protection for both product and operator. The filling line, fitted with semi-auto de-bagger and an automatic vial-capping machine, offers a fully-automated method for filling and closing of syringes and vials.
The line also contains a highly special lyophiliser able to handle high potency compounds and flammable liquids. “Whether you are looking for a contract manufacturer or a development partner, the Basic Pharma team is ready to support you and listen to your needs to make your project a success,” states Cyrille Delahaye, Director of operations of Basic Pharma.

In addition to PFS, Basic Pharma’s strong focus on pharmaceutical development, licensing, and manufacturing of both non-sterile and aseptic products has helped the company establish a good reputation in the pharmaceutical and biopharmaceutical market. Basic Pharma also provides a full package of laboratory services around pharmaceutical liquids and semi-solids for the pharmaceutical, biotech, and medical device industry. To this end, Basic Pharma’s development division coordinates and executes multiple projects, including co-financed projects for both generic and innovative medicines. The successful completion of such projects results in product registrations in various countries. To execute such projects efficiently, Interdos—the professional service and consultancy wing of Basic Pharma—submits product dossiers for registration in several markets while the manufacturing division handles production and distribution. The activities of the technology wing, on the other hand, help in growing the current product pipeline of Basic Pharma. “Along with our proprietary pharmaceutical products, we also act as our clients’ preferred contract manufacturer for their pharmaceutical or biotech products, both investigational medicinal products (IMPs) and commercial products,” highlights Bob Kool, chief business development officer and managing director of Basic Pharma. With this comprehensive service package, the company covers the entire chain from product development, licensing, and production up to its sales and distribution.

Having already established itself as a trusted CMO specialised in PFS and other pharmaceutical products, Basic Pharma is now planning to focus on more generic pharmaceutical product developments. Furthermore, the company also intends to work on the out-licensing of those newly developed products. For the coming months, geographic expansion across Europe is one of the top priorities for Basic Pharma. With such ambitious plans in its roadmap, Basic Pharma is poised to become the preferred supplier for prefilled syringes and (loyphilsed) vials.
Share this Article:
Basic Pharma Group

Company
Basic Pharma Group

Headquarters
Geleen, The Netherlands

Management
Cyrille Delahaye, Director of operations and Peter Hollanders, Business Development Director Bob Kool, Managing Director

Description
The CMO maintains an entirely multi-purpose, aseptic PFS and vial filling line for liquid and lyophilized injectable products. Housed at the company’s GMP-certified facility at the Brightlands Chemelot Research Campus in the Netherlands, the aseptic filling line operates in a class ‘A’ isolator, which guarantees an aseptic production process, thus ensuring protection for both product and operator. The filling line, offers a fully-automated method for filling and closing of syringes and vials. The line also contains a highly special lyophiliser able to handle high potency compounds and flammable liquids. The company is primarily engaged in the development, licensing, and manufacturing of registered and non-registered pharmaceutical products, and investigational medicinal products, along with laboratory services for the pharmaceutical, biotech, and medical device industry